1
NR 567 Midterm
NR 567 Midterm Exam Study Guide for Advanced
Pharmacology Questions with Correct Verified
Answers (Latest 2026/2027)
1.What laboratory parameters should be monitored when administering
thrombolytics?: CBC, PT/INR, and PTT.
2.What is the recommended dosing for alteplase in acute myocardial infarction
(MI)?: 100 mg total: 15 mg IV bolus, 50 mg over 30 minutes, and 35 mg over
60 minutes.
3.What is the bioavailability of alteplase when administered IV?: 100% due to
IV administration.
4.How is alteplase metabolized?: Rapid hepatic clearance, mainly by the liver
through internalization and catabolism by hepatic cells.
5.What is the initial elimination half-life of alteplase?: About 5 minutes (rapid
plasma clearance).
NR 567 Midterm
, .
6.What is the terminal elimination half-life of alteplase?: About 35-50 minutes
(slower elimination).
7.What is the mechanism of action of statins like lovastatin?: Statins inhibit
HMG-CoA reductase in the liver, reducing cholesterol synthesis and lowering
LDL cholesterol levels.
8.What are the medications used in acute pulmonary embolism?: Heparin and
alteplase (Activase).
16 What is the recommended dosage of alteplase for pulmonary embolism?:
100 mg infused IV over 2 hours.
17. What are the side effects and adverse effects of thrombolytics?:
Bleeding, including major bleeding risks and intracranial hemorrhage.
18. What precautions should be taken when administering thrombolytics?:
Monitor for contraindications such as prior intracranial hemorrhage and
active internal bleeding.
19. What is the route of administration for alteplase?: IV only.
, .
20. What is the significance of monitoring coagulation parameters in patients
receiving thrombolytics?: To assess bleeding risk and ensure safe
administration.
21. What is the pharmacokinetic property of alteplase regarding its
distribution?: It is mostly distributed in plasma.
22. What are the key concepts to remember regarding drug classes in this
course?: Know the drug class and individual generic drug names, mechanisms
of action, pharmacokinetics, side effects, and contraindications.
23. What is the time frame for monitoring after administering
thrombolytics?: -
Continuous monitoring for signs of bleeding and changes in coagulation
parameters.
24. What is the importance of understanding pharmacodynamics in drug
administration?: It helps predict how the drug affects the body and informs
safe and effective dosing.
, .
25. What is the primary use of statins after myocardial infarction (MI)?: To
reduce the risk of death, recurrent myocardial infarction, and
thromboembolic events such as stroke or systemic embolization.
26. What are the potential side effects of statins?: Hepatotoxicity, myopathy,
and rhabdomyolysis.
27. What does hepatotoxicity indicate in patients taking statins?: Increased
liver enzymes indicating potential liver damage.
28. What should be monitored to assess muscle breakdown in patients on
statins?: CK lab values.
29. What precautions should be taken before starting statin treatment?:
Perform liver function tests prior to initiating treatment and when clinically
indicated.
30. Why should statins be used cautiously in elderly clients?: Due to an
increased risk of muscle-related side effects.
31. What specific consideration should be made for clients of Asian descent
regarding statin use?: Certain statins, particularly rosuvastatin, may cause
toxicity due to altered metabolism. 32 What drug interactions should be
NR 567 Midterm
NR 567 Midterm Exam Study Guide for Advanced
Pharmacology Questions with Correct Verified
Answers (Latest 2026/2027)
1.What laboratory parameters should be monitored when administering
thrombolytics?: CBC, PT/INR, and PTT.
2.What is the recommended dosing for alteplase in acute myocardial infarction
(MI)?: 100 mg total: 15 mg IV bolus, 50 mg over 30 minutes, and 35 mg over
60 minutes.
3.What is the bioavailability of alteplase when administered IV?: 100% due to
IV administration.
4.How is alteplase metabolized?: Rapid hepatic clearance, mainly by the liver
through internalization and catabolism by hepatic cells.
5.What is the initial elimination half-life of alteplase?: About 5 minutes (rapid
plasma clearance).
NR 567 Midterm
, .
6.What is the terminal elimination half-life of alteplase?: About 35-50 minutes
(slower elimination).
7.What is the mechanism of action of statins like lovastatin?: Statins inhibit
HMG-CoA reductase in the liver, reducing cholesterol synthesis and lowering
LDL cholesterol levels.
8.What are the medications used in acute pulmonary embolism?: Heparin and
alteplase (Activase).
16 What is the recommended dosage of alteplase for pulmonary embolism?:
100 mg infused IV over 2 hours.
17. What are the side effects and adverse effects of thrombolytics?:
Bleeding, including major bleeding risks and intracranial hemorrhage.
18. What precautions should be taken when administering thrombolytics?:
Monitor for contraindications such as prior intracranial hemorrhage and
active internal bleeding.
19. What is the route of administration for alteplase?: IV only.
, .
20. What is the significance of monitoring coagulation parameters in patients
receiving thrombolytics?: To assess bleeding risk and ensure safe
administration.
21. What is the pharmacokinetic property of alteplase regarding its
distribution?: It is mostly distributed in plasma.
22. What are the key concepts to remember regarding drug classes in this
course?: Know the drug class and individual generic drug names, mechanisms
of action, pharmacokinetics, side effects, and contraindications.
23. What is the time frame for monitoring after administering
thrombolytics?: -
Continuous monitoring for signs of bleeding and changes in coagulation
parameters.
24. What is the importance of understanding pharmacodynamics in drug
administration?: It helps predict how the drug affects the body and informs
safe and effective dosing.
, .
25. What is the primary use of statins after myocardial infarction (MI)?: To
reduce the risk of death, recurrent myocardial infarction, and
thromboembolic events such as stroke or systemic embolization.
26. What are the potential side effects of statins?: Hepatotoxicity, myopathy,
and rhabdomyolysis.
27. What does hepatotoxicity indicate in patients taking statins?: Increased
liver enzymes indicating potential liver damage.
28. What should be monitored to assess muscle breakdown in patients on
statins?: CK lab values.
29. What precautions should be taken before starting statin treatment?:
Perform liver function tests prior to initiating treatment and when clinically
indicated.
30. Why should statins be used cautiously in elderly clients?: Due to an
increased risk of muscle-related side effects.
31. What specific consideration should be made for clients of Asian descent
regarding statin use?: Certain statins, particularly rosuvastatin, may cause
toxicity due to altered metabolism. 32 What drug interactions should be
